Jane Huang, M.D.

Equibles does not estimate personal net worth.

About Jane Huang, M.D.

Prelude Therapeutics Inc reported in an 8-K filed November 4, 2025 that Jane Huang, M.D. resigned as President and Chief Medical Officer, effective November 3, 2025.

“On November 4, 2025, the Company announced that Jane Huang, M.D. resigned as the President and Chief Medical Officer of the Company, effective on November 3, 2025 (the "Separation Date").”

Prelude Therapeutics Inc Form 8-K, filed November 4, 2025 · Read the filing

Affiliation history

Prelude Therapeutics Inc (PRLD)
SEC 8-K

2022-04-04–2025-11-03

Company network

Prelude Therapeutics Inc

PRLD

Biotechnology · Healthcare

Recent activity

Executive change Resigned: President and Chief Medical Officer Prelude Therapeutics Inc (PRLD)
2025-11-03